z-logo
open-access-imgOpen Access
Drug susceptibility pattern in organisms isolated during acute exacerbation of Chronic Obstructive Pulmonary Disease
Author(s) -
Sanjeet Krishna Shrestha,
Raina Chaudhary,
Sabita Bhatta,
Manan Karki,
B. N. Srivastava,
Rabindra Khunjeli,
Ushab Rana Mousin,
Jyoti Shrestha
Publication year - 2016
Publication title -
medical journal of shree birendra hospital/medical journal of shree birendra hospital
Language(s) - English
Resource type - Journals
eISSN - 2091-0193
pISSN - 2091-0185
DOI - 10.3126/mjsbh.v15i1.14125
Subject(s) - medicine , acinetobacter , sputum , exacerbation , copd , microbiology and biotechnology , drug resistance , bacilli , pseudomonas aeruginosa , gastroenterology , antibiotics , bacteria , tuberculosis , biology , pathology , genetics
Disease process in chronic obstructive lung disease is interrupted by acute exacerbations. Bacterial and viral infections accounts for majority of cases. Gram positive and Gram Negative organism are both associated. Materials and Methods Sputum samples were collected from COPD patients in acute exacerbation, on the day of emergency visit. Drug susceptibility pattern was evaluated for the study population to identify the prevalence of susceptible and resistant organisms. Results Eighty-nine culture positive sputum samples were processed for drug susceptibility. Gram negative bacilli (88.76%) were isolated more than Gram positive cocci (11.24%). Pseudomonas sp. , Acinetobacter sp. , Klebseilla sp. and E. coli were the most common Gram negative bacilli. Multi-drug resistance status was identified in higher percents in Acinetobacter sp . (81.25%), Pseudomonas sp . (62.5%) and Klebseilla sp. (46.6%). Aminoglycosides and Quinolones showed good sensitivity to GNBs. However, Carbapenems were found to be the most effective agents against these organisms. Conclusion Gram negative infection is common in COPD. Multi drug resistant pathogens are increasingly associated with acute exacerbations. Routinely used antibiotics are becoming less effective.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here